Clinical Trials Logo
  1. Home
  2. NSCLC, Stage III
  3. NCT04202809

Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. — ESPADURVA  

NSCLC, Stage III Clinical Trial

Official title:
Prospective Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus the PD-L1 Antibody Durvalumab Followed by Surgery or Definitive Chemoradiation Boost and Consolidation Durvalumab in Resectable Stage III NSCLC.

Clinical Trial Summary

To compare a complex induction multimodality protocol (ESPATUE) + concurrent immunotherapy with PD-L1 antibody Durvalumab given every three weeks to the same induction multimodality protocol without Durvalumab immunotherapy induction followed by definitive local treatment (surgery for those considered resectable or chemoradiation boost for those not considered to be R0-resectable) followed by consolidation Durvalumab treatment in both arms.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04202809
Study type Interventional
Source University Hospital, Essen
Contact Andrea Moell, PhD
Phone 0049 201 72377412
Email andrea.moell@uk-essen.de
Status Recruiting
Phase Phase 2
Start date January 13, 2020
Completion date April 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05386888 - A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC Phase 2
Recruiting NCT05128630 - Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC. Phase 2
Active, not recruiting NCT05027165 - Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
Recruiting NCT05311709 - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities Phase 2
Recruiting NCT04351256 - Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy Phase 2
Active, not recruiting NCT04392505 - Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study Phase 2
Recruiting NCT05611879 - Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC Phase 2
Recruiting NCT05718297 - Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT06467383 - A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
Recruiting NCT04952168 - Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC Phase 2
Recruiting NCT04830826 - A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
Recruiting NCT05757843 - Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab Phase 2
Active, not recruiting NCT03999710 - Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer Phase 2
Recruiting NCT03454685 - The Role of Microbiota on the Development of Lung Cancer
Not yet recruiting NCT05177497 - SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC Phase 2
Recruiting NCT04585490 - Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC Phase 3
Recruiting NCT04654364 - Lung Cancer Registry
Recruiting NCT05344209 - Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer Phase 2
Withdrawn NCT03130829 - To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC N/A
Recruiting NCT04680377 - Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients